166 related articles for article (PubMed ID: 34649722)
1. [De-escalation strategies in differentiated thyroid cancer].
Hartl DM; Hadoux J; Garcia C; Ghuzlan AA; Guerlain J; Breuskin I; Baudin E; Lamartina L
Bull Cancer; 2021 Dec; 108(12):1132-1144. PubMed ID: 34649722
[TBL] [Abstract][Full Text] [Related]
2. Radioactive iodine does not improve overall survival for patients with aggressive variants of papillary thyroid carcinoma less than 2 cm.
Holoubek SA; MacKinney EC; Khokar AM; Kuchta KM; Winchester DJ; Prinz RA; Moo-Young TA
Surgery; 2022 Jan; 171(1):203-211. PubMed ID: 34384604
[TBL] [Abstract][Full Text] [Related]
3. [The course of differentiated thyroid microcarcinoma in patients treated by different therapeutic strategies].
Grigerová M; Griger M; Mojtová E; Podoba J
Vnitr Lek; 2016; 62(9 Suppl 3):17-21. PubMed ID: 27734686
[TBL] [Abstract][Full Text] [Related]
4. NIFT-P: Are they indolent tumors? Results of a multi-institutional study.
Chereau N; Greilsamer T; Mirallié E; Sadowski SM; Pusztaszeri M; Triponez F; Baud G; Pattou F; Christou N; Mathonnet M; Brunaud L; Santucci N; Goudet P; Guérin C; Sebag F; Donatini G; Kraimps JL; Tissier F; Lussey-Lepoutre C; Leenhardt L; Menegaux F
Surgery; 2019 Jan; 165(1):12-16. PubMed ID: 30420090
[TBL] [Abstract][Full Text] [Related]
5. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer.
Mazzaferri EL; Jhiang SM
Am J Med; 1994 Nov; 97(5):418-28. PubMed ID: 7977430
[TBL] [Abstract][Full Text] [Related]
6. Risk-oriented concept of treatment for intrathyroid papillary thyroid cancer.
Hartl DM; Hadoux J; Guerlain J; Breuskin I; Haroun F; Bidault S; Leboulleux S; Lamartina L
Best Pract Res Clin Endocrinol Metab; 2019 Aug; 33(4):101281. PubMed ID: 31208873
[TBL] [Abstract][Full Text] [Related]
7. Management of thyroid cancer: United Kingdom National Multidisciplinary Guidelines.
Mitchell AL; Gandhi A; Scott-Coombes D; Perros P
J Laryngol Otol; 2016 May; 130(S2):S150-S160. PubMed ID: 27841128
[TBL] [Abstract][Full Text] [Related]
8. Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial.
Dehbi HM; Mallick U; Wadsley J; Newbold K; Harmer C; Hackshaw A
Lancet Diabetes Endocrinol; 2019 Jan; 7(1):44-51. PubMed ID: 30501974
[TBL] [Abstract][Full Text] [Related]
9. Improving postoperative recurrence rates for carcinoma of the thyroid gland.
McHenry C; Jarosz H; Lawrence AM; Paloyan E
Surg Gynecol Obstet; 1989 Nov; 169(5):429-34. PubMed ID: 2814754
[TBL] [Abstract][Full Text] [Related]
10. Reoperative lymph node dissection for recurrent papillary thyroid cancer and effect on serum thyroglobulin.
Hughes DT; Laird AM; Miller BS; Gauger PG; Doherty GM
Ann Surg Oncol; 2012 Sep; 19(9):2951-7. PubMed ID: 22526913
[TBL] [Abstract][Full Text] [Related]
11. Low risk papillary thyroid cancer.
Brito JP; Hay ID; Morris JC
BMJ; 2014 Jun; 348():g3045. PubMed ID: 24935445
[TBL] [Abstract][Full Text] [Related]
12. Evaluating the 2015 American Thyroid Association Risk Stratification System in High-Risk Papillary and Follicular Thyroid Cancer Patients.
van Velsen EFS; Stegenga MT; van Kemenade FJ; Kam BLR; van Ginhoven TM; Visser WE; Peeters RP
Thyroid; 2019 Aug; 29(8):1073-1079. PubMed ID: 31140385
[No Abstract] [Full Text] [Related]
13. Papillary thyroid carcinoma: the impact of therapy in 576 patients.
Mazzaferri EL; Young RL; Oertel JE; Kemmerer WT; Page CP
Medicine (Baltimore); 1977 May; 56(3):171-96. PubMed ID: 859443
[No Abstract] [Full Text] [Related]
14. Recurrence predictability by various staging systems in 283 patients after thyroidectomy and radioactive iodine treated for papillary thyroid carcinoma.
Yaniv D; Mizrachi A; Raz R; Tzelnick S; Feinmesser R; Hamzany Y; Vaisbuch Y; Hilly O
Clin Otolaryngol; 2019 Nov; 44(6):1147-1152. PubMed ID: 31437357
[No Abstract] [Full Text] [Related]
15. Frequent screening with serial neck ultrasound is more likely to identify false-positive abnormalities than clinically significant disease in the surveillance of intermediate risk papillary thyroid cancer patients without suspicious findings on follow-up ultrasound evaluation.
Peiling Yang S; Bach AM; Tuttle RM; Fish SA
J Clin Endocrinol Metab; 2015 Apr; 100(4):1561-7. PubMed ID: 25632970
[TBL] [Abstract][Full Text] [Related]
16. Which is preferred for initial treatment of papillary thyroid cancer, total thyroidectomy or lobotomy?
Wu Z; Han L; Li W; Wang W; Chen L; Yao Y; Wang Y
Cancer Med; 2021 Mar; 10(5):1614-1622. PubMed ID: 33512778
[TBL] [Abstract][Full Text] [Related]
17. Robot-assisted Sistrunk's operation, total thyroidectomy, and neck dissection via a transaxillary and retroauricular (TARA) approach in papillary carcinoma arising in thyroglossal duct cyst and thyroid gland.
Byeon HK; Ban MJ; Lee JM; Ha JG; Kim ES; Koh YW; Choi EC
Ann Surg Oncol; 2012 Dec; 19(13):4259-61. PubMed ID: 23070784
[TBL] [Abstract][Full Text] [Related]
18. Predictors for papillary thyroid cancer persistence and recurrence: a retrospective analysis with a 10-year follow-up cohort study.
de Castro TP; Waissmann W; Simões TC; de Mello RC; Carvalho DP
Clin Endocrinol (Oxf); 2016 Sep; 85(3):466-74. PubMed ID: 26834009
[TBL] [Abstract][Full Text] [Related]
19. High-dose radioactive iodine therapy is associated with decreased risk of recurrence in high-risk papillary thyroid cancer.
Gray KD; Bannani S; Caillard C; Amanat S; Ullmann TM; Romanov P; Brunaud L; Beninato T; Fahey TJ; Mirallie E; Zarnegar R
Surgery; 2019 Jan; 165(1):37-43. PubMed ID: 30274732
[TBL] [Abstract][Full Text] [Related]
20. Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients.
Loh KC; Greenspan FS; Gee L; Miller TR; Yeo PP
J Clin Endocrinol Metab; 1997 Nov; 82(11):3553-62. PubMed ID: 9360506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
